Bevacizumab (AVASTIN) ELISA Assay Kit
The Bevacizumab (AVASTIN) ELISA Assay Kit is For Research Use Only
Size: 12 x 8 wells
Sensitivity: 0.03 ug/mL
Standard Range: 0 – 100 ug/mL
Incubation Time: 1 hour 10 minutes
Sample Type: Serum, Plasma
Sample Size: 10 µL
Alternative Name: Avastin
Assay Background
Bevacizumab is a monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer. There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. It is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and neutralizing VEGF-A. Bevacizumab is generally indicated for use in combination with different chemotherapy regimens which are specific to the type, severity, and stage of cancer. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.
Assay Principle
Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Standards and samples (serum or plasma) are incubated in the microtiter plate coated with the reactant for bevacizumab. After incubation, the wells are washed. Then, horse radish peroxidase (HRP) conjugated probe is added and binds to bevacizumab captured by the reactant on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of bevacizumab in the sample or standard. Results of samples can be determined directly using the standard curve.
Related Products
Anti-Bevacuzimab (Avastin) ELISA Kit
Bevacizumab mAb-based ELISA Assay
Trastuzumab (Herceptin) ELISA
